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Novel Mastoparan Analogs Induce
Differential Secretion from Mast Cells
[3]. The chimeric construct M391 ([phenylacetyl-D-
Tyr(Me)2Arg6Tyr9]AVP-εAhx-MP), combining a linear va-
sopressin receptor antagonist [8] and MP separated by
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and John Howl1,3
a flexible aminohexanoic-acid linker, selectively binds1Molecular Pharmacology Group
with high affinity to the V1a vasopressin receptor [7]. LikeSchool of Health Sciences
galparan, M391 can also influence biological function byUniversity of Wolverhampton
mechanisms that are independent of G protein-coupled62-68 Lichfield Street
receptor interaction and is a potent insulin secretagogWolverhampton WV1 1DJ
[4]. These findings indicate that chimeric analogs of MPUnited Kingdom
can specifically modify the function of both extracellular2 Department of Neurochemistry
and intracellular proteins and provide valuable tools toand Neurotoxicology
study and modulate biological phenomena.Arrhenius Laboratories for Natural Sciences
In order for peptidyl secretagogs to bind G proteins orStockholm University
other intracellular targets, there is clearly a fundamentalS-106 91 Stockholm
requirement that the peptide can translocate across theSweden
plasma membrane. In the case of MP, interaction with
biological membranes and activation of G proteins ap-
pear to be largely dependent upon amphiphilicity and
the adoption a helical structure in a lipidic environmentSummary
[9, 10]. Clear evidence that chimeric peptides such as
galparan can penetrate eukaryotic cells is provided byCationic amphiphilic peptides stimulate secretion via
studies with the structural homolog transportan (gal-a receptor-independent action upon G proteins [1].
anin(1-12)-Lys-MP [11]). Biophysical and biochemicalWe have previously utilized chimeric analogs of masto-
studies indicate that transportan, and a variety of dele-paran (MP), including galparan (galanin(1–13)-MP [2]), as
tion analogs, penetrate eukaryotic cells by a nonendocy-molecular probes of secretion [3, 4]. Here, we further
totic mode of transport [12, 13]. In addition to a complexresolve the structure-activity relationship of peptidyl
influence on GTPase activity (see Discussion), other pu-
secretagogs, including rationally designed chimeric
tative intracellular targets for MP analogs include the
MP analogs. The secretory efficacies of 10 MP analogs Ca2-ATPase and the ryanodine receptor of the endo-
were significantly higher than 45 unrelated basic pep- plasmic reticulum [14]. Intriguingly, MP, galparan, and
tides. Comparative studies identified MP analogs that M391 inhibit Ca2-ATPases and activate the ryanodine
are differential secretagogs for 5-hydroxytryptamine receptor, leading to net Ca2-release from endoplasmic
(5-HT) and -hexosaminidase. Peptide-induced acti- reticulum in vitro [14].
vation of phospholipase D (PLD), an enzyme intimately The above observations, along with many other exam-
involved in regulated exocytosis [5], correlated with ples of the ability of MP and galparan to influence cellular
the secretion of-hexosaminidase but not 5-HT. Thus, activity [15], prompted this investigation, in which we
these data indicate that different mechanisms are re- further address the utility of structurally diverse MP ana-
sponsible for the exocytosis of 5-HT and-hexosamin- logs as secretagogs. For this purpose, we utilized RBL-
idase, respectively. Moreover, mastoparan analogs 2H3, a well-documented model of secretory mucosal
are novel tools for probing the molecular details of mast cells [16]. To facilitate the detailed comparison of
exocytosis and other biological phenomena. MP analogs with other cationic peptides, we synthe-
sized three additional chimeric MP analogs by using
sequences reported to modulate secretion as amino-
Introduction terminal extensions [17, 18, 19]. Our comparative stud-
ies, utilizing a total of 56 peptides, revealed a majority
of peptides that did not influence the exocytosis of eitherGalparan (galanin(1–13)-MP; GWTLNSAGYLLGPINLKA
5-HT or the secretory lysosomal marker -hexosamini-LAALAKKIL-NH2 [2]) was synthesized as part of a pro-
dase. These studies clearly endorse the unique proper-gram aimed at developing selective ligands for galanin
ties of the MP sequence and its chimeric constructsreceptors. In addition to being a galanin receptor ligand,
that interact with multiple intracellular sites to regulategalparan displays unique biological activities, indepen-
secretory pathways and activate PLD. Moreover, ourdent of receptor binding, that include the activation of
studies reveal that certain MP analogs are differentialrat brain Na,K-ATPase [2] and the inhibition of GTPase
secretagogs that could prove to be valuable probes ofactivity [6]. Moreover, galparan is a powerful insulin-
other cellular systems, such as the pancreatic B cell.releasing peptide, acting at a distal site distinct from
the locus of action of MP, in the B cell secretory pathway
Results
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of Basic Peptides4 Present address: The Harold L Dorris Neurological Research Cen-
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Table 1. Primary Sequences of Peptides Compared in This Study
Sequences Related to Small Peptide Hormones and Neuropeptides
Bradykinin (BK) RPPGFSPFR-OH
Des-Arg9BK RPPGFSPF-OH
[Aib7]BK RPPGFSAibFR-OH
[Thi5,8D-Phe7]BK RPPGThiSfThiR-OH
Lys0BK KRPPGFSPFR-OH
H2N-(R)-BK-ac CH3CO-rfpsfGppr-NH2
Arginine vasopressin (AVP) CYFQNCPRG-NH2
[Aib4]AVP CYFAibNCPRG-NH2
[Aib7]AVP CYFQNCAibRG-NH2
AVP-BK CYFQNCPRGRPPGFSPFR-OH
RGDF-Ahx-D-Arg0[Hyp3DPhe7Leu8]BK RGDFAhxrRPHypGFSfLR-OH
[Pa-D-T-yr2Val4Arg6Aib7Arg(NH2)9]AVP Pa-yFVNRAibRR-NH2
[Pa-D-Tyr2Aib4Arg6Arg(NH2)9]AVP Pa-yFAibNRPRR-NH2
[Phaa-D-Tyr(Et)2Aib4Arg6Tyr(NH2)9]AVP Phaa-y(Et)FAibNRPRY-NH2
[Phaa-D-Tyr(Et)2Arg6Aib7Tyr(NH2)9]AVP Phaa-y(Et)FQNRAibRY-NH2
[Phaa-D-Tyr(Et)2Arg6]AVP(1-8)-Ahx-RGDF-NH2 Phaa-y(Et)FQNRPRAhxRGDF-NH2
[Phaa-D-Tyr(Et)2Arg6]AVP(1-9)-DF-NH2 Phaa-y(Et)FQNRPRGDF-NH2
[d(CH2)5-D-Tyr(Et)2Lys3Val4Arg(NH2)9]AVP d[CH2)5-y(Et)KVNCPRR-NH2
[d(CH2)5-D-Tyr(Et)2Lys3Val4]AVP d(CH2]5-y(Et)KVNCPRG-NH2
BK(1)-AVP(2-5)-BK(6-9) RYFQNSPFR-OH
H2N-(R)-ATII fphiyvrd-NH2
Oxytocin CYIQNCPLG-NH2
Neurotensin PyrLYENKPRRPYIL-OH
Endothelin-1 CSCSSLMDKECVYFCHLDIIW-OH
Bombesin PyrQRLGNQWAVGHLM-NH2
Substance K HKTDSFVGLM-NH2
Substance P RPKPQQFFGLM-NH2
Salmon calcitonin CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-NH2
M32, Gal(1-13)-NPY(25-36) GWTLNSAGYLLGPRHYINLITRQRY-NH2
M88, Gal(1-12)-Ala-NPY(25-36) GWTLNSAGYLLGARHYINLITRQRY-NH2
M35, Gal(1-13)-BK(2-9)-NH2 GWTLNSAGYLLGPPPGFSPFR-NH2
M58, Gal(1-13)-BK(2-9) GWTLNSAGYLLGPPPGFSPFR-OH
M59, Gal(1-13)-BK(2-8)-NH2 GWTLNSAGYLLGPPPGFSPF-NH2
M69A, Gal(1-13)-Lys-[NH-Gly-NPY(4-1)]-NPY(25-36) GWTLNSAGYLLGPK(NH-GKSPY)RHYINLITRQRY-NH2
M120, Gal(1-13)-NPY(14-36) GWTLNSAGYLLGPAEDLARYYSALRHYINLITRQRY-NH2
Mastoparan (MP)-Containing Sequences
MP INLKALAALAKKIL-NH2
MP S INWKGIASMAibRQVL-NH2
QLKK-MP QLKKINLKALAALAKKIL-NH2
SFLLR-MP SFLLRINLKALAALAKKIL-NH2
ZGF-MP ZGFINLKALAALAKKIL-NH2
M391, [PhaaDTyr(Me)2Arg6Tyr9]AVP-Ahx-MP Phaa-y(Me)FQNRPRYAhxINLKALAALAKKIL-NH2
M432, MP-hCGRP(28-37) INLKALAALAKKILVPTNVGSKAF-NH2
M435, hCGRP(1-15)-MP ACDTATCVTHRLAGLINLKALAALAKKIL-NH2
M436, MP-hCGRP(8-18)(28-37) INLKALAALAKKILVTHRLAGLLSRVPTNVGSKAF-NH2
Galparan, galanin(1-13)-MP GWTLNSAGYLLGPINLKALAALAKKIL-NH2
Receptor-derived sequences
Rat Vla receptor9–24, (rVlaR9–24) DRSVGNSSPWWPLTTE-NH2
rVlaR39–52 DSPLGDVRNEELAK-NH2
rVlaR185–194 EVNNGTKTQD-NH2
Rat V2 receptor100–111 DATDRFHGPDAL-NH2
Human P2Y2 receptor14–27 (hP2Y2R14–27) GTWDGDELGRYCRF-NH2
hP2Y2R94–107 RGDHWPFSTVLCKL-NH2
hP2Y2R174–187 SARGGRVTCHDTSA-NH2
hP2Y2R180–193 VTCHDTSAPELFSR-NH2
hP2Y2R271–284 RSLDLSCHTLNAIN-NH2
L312, Cys-VE cadherin625–637 CRKQARAHGKSVPE-NH2
L313, Cys-VE cadherin755–766 CVDYDFLNDWGPR-NH2
(continued)
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Table 2. Biological Activities of Peptidyl Secretagogs
Secretion (Fold/Basal) Efficacy Index
Secretory PLD Activity Efficacy
Peptide 5-HT -Hexosaminidase 5-HT -Hexosaminidase Efficacy Ratio (Fold/Basal) Index PLD
MP 12.86  0.51 7.64  1.06 1.00 1.00 1.00 2.85  0.60 1.00
M432 3.07  0.36 1.70  0.11 0.16 0.11 1.45 1.36  0.14 0.19
M435 14.26  2.29 7.73  0.32 1.12 1.01 1.11 1.75  0.19 0.41
M436 13.97  1.09 4.31  0.76 1.09 0.50 2.18 1.20  0.09 0.11
Galparan 4.89  0.86 7.97  0.95 0.33 1.05 0.31 5.39  1.43 2.37
M391 5.65  0.68 6.93  0.47 0.39 0.89 0.44 5.07  1.56 2.20
MP S 2.72  0.23 10.68  1.52 0.15 1.46 0.10 2.07  0.39 0.58
QLKK-MP 1.78  0.11 3.17  0.43 0.07 0.33 0.21 1.84  0.23 0.45
SFLLR-MP 2.89  0.34 7.81  0.62 0.16 1.03 0.16 4.21  0.78 1.74
ZGF-MP 3.54  0.45 9.75  1.02 0.21 1.32 0.16 5.08  0.36 2.21
M120 1.87  0.29 0.85  0.11 0.07 n.a. n.a. 0.81  0.01 n.a.
Substance P 3.28  1.17 1.06  0.13 0.19 0.01 19.00 0.90  0.07 n.a.
Data indicating secretion (fold/basal) and PLD activation (fold/basal) are mean  SEM of three independent determinations at a final peptide
concentration of 3  105 M. Efficacy indices express the above basal activities of secretagogs as a fraction of the activity of MP, which is
ascribed a value of 1.00 in all assays. Secretory efficacy ratios are calculated as the efficacy ratio 5-HT/efficacy ratio -hexosaminidase.
Throughout the text the term “selective” is used to describe a peptidyl secretagog with an efficacy ratio of 2 or 0.5.
range of cell types. Our initial studies were designed to mastoparans, combining MP with sequences known to
modify secretion, were relatively weak 5-HT secre-reassess this phenomenon by evaluating the secretory
efficacies of 56 peptides that, with the exception of tagogs (efficacy indices  0.5, Table 2).
Comparative data measuring -hexosaminidase se-oxytocin, contain one or more basic residues (Lys or Arg;
Table 1). As indicated in Table 1, the chosen peptides cretion revealed a distinctly different pattern of results.
Intriguingly, MP S, a reported Gs-selective analog of MP,included 35 monomeric and chimeric sequences related
to hormones and neuropeptides, ten MP-related se- proved to be the most potent and selective activator of
-hexosaminidase secretion (efficacy ratio 0.10, Tablequences, and a group of 11 peptides representing se-
quences from extracellular domains of G protein-cou- 2). Of the chimeric constructs, both galparan and ZGF-
MP were more potent and selective activators ofpled receptors and the intracellular domains of VE
cadherin. The secretory efficacies of all peptides, at -hexosaminidase secretion than MP (Table 2).
Figure 2 directly compares the potencies of peptidylconcentrations of 1–100 	M, were determined via
assays of both 5-HT and -hexosaminidase exocytosis. secretagogs for both 5-HT and -hexosaminidase se-
cretion and further reveals a lack of correlation betweenThese studies clearly endorsed the unique properties
of MP and selected analogs as potent peptidyl secre- the two data sets. This lack of correlation is confirmed
by statistical analysis (Spearman r 
 0.210; p 
 0.514).tagogs of both 5-HT and -hexosaminidase (Table 2;
Figure 1). Significantly, all other sequences displayed These comparative data revealed three broad classes
of peptidyl secretagogs. Class 1, including QLKK-MP,weak (substance P and M120, Table 2) or zero secretory
efficacies in either assay system. M432, and substance P, were relatively weak secre-
tagogs (efficacy indices  0.5) of both 5-HT and
-hexosaminidase. Despite its relatively low potency,Mastoparan Analogs Are Differential Secretagogs
Data presented in Figure 1 and summarized in Table 2 substance P, with an efficacy ratio of 19 (Table 2), was
the most selective activator of 5-HT secretion. Class 2,clearly indicate that analogs of MP displayed a range
of secretory efficacies that can surpass that of MP in the quantitatively dominant group, contained MP S and
four chimeric constructs that were selective activatorseither assay system. The composite effects of both
amino- and carboxy-terminal extension of MP in chime- of -hexosaminidase secretion (-hexosaminidase effi-
cacy indices  0.5, 5-HT efficacy indices  0.5). Classric constructs were dependent on both the secretory
mechanism and the sequence. Significantly, M435 and 3 contained MP, M435, and M436, peptides that were
potent activators (efficacy indices  0.5) of both -hex-M436, analogs of MP extended by sequences of hCGRP
at the amino- and carboxy-temini, respectively, dis- osaminidase and 5-HT secretion. With an efficacy ratio
of 2.18, M436 represents the only potent peptidyl secre-played similar potencies to MP in 5-HT secretion assays
(Table 2). All other amino-terminally extended chimeric tagog that was relatively selective for 5-HT.
Table 1 continued.
Details of the synthesis, purification, and biological properties of many of these peptides are reported in references [2, 4, 7, 20–30]. Basic
residues are underlined. Abbreviations are as follows: Ahx, 6-aminohexanoic acid; Aib, -aminoisobutyric acid; AVP, [Arg8]vasopressin;
d(CH2)5, -mercapto-,-cyclopentamethylene propionic acid; BK, bradykinin; Gal, galanin; hCGRP, human calcitonin gene-related peptide;
MP, mastoparan; NPY, neuropeptide Y; Pyr, L-pyroglutamic acid; Thi, -thienyl-L-alanine; DTyr(Me), O-methyl-D-tyrosine; DTyr(Et), O-ethyl-
D-tyrosine; Pa, propionic acid; Phaa, phenylacetic acid; and Z, benzyloxycarbonyl. D amino acids are prefixed by D when triplet nomenclature
is used, and they are presented as lowercase symbols when single-letter nomenclature is used. (R) indicates a retro-inverso peptide synthesized
in reverse sequence from mostly D amino acids.
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Figure 2. Comparison of the Efficacy Indices of Peptidyl Secre-
tagogs
Symbols used to specify three different classes of peptidyl secre-
tagog (see text) indicate: (squares) selective, high-efficacy -hexos-
aminidase secretagogs; (circles) Non-selective, high-efficacy secre-
tagogs; and (triangles) relatively low-efficacy secretagogs. This
figure also indicates the lack of correlation between the secretory
indices of individual secretagogs.
dex of PLD activation. Figure 3 indicates that the activa-
tion of PLD by peptidyl secretagogs was a complex and
concentration-dependent phenomenon. As summa-
rized in Table 2, the rank order of potency for PLD activa-
tion was galparan  ZGF-MP 
 M391  SFLLR-MP 
MP  QLKK-MP 
 M435  M432 
 M436. Both sub-
stance P and M120 were weak antagonists of PLD at
30 	M (Table 2).
Comparative data indicated fundamental differences
in the contribution of PLD activity to the secretion of
5-HT or-hexosaminidase (Figure 4). No causal relation-
ship was observed when PLD activation and 5-HT secre-
tion were compared (Figure 4A), a result confirmed by
Figure 1. Peptide-Induced Secretion of 5-HT and -Hexosamin- Spearman correlation analysis (r 
 0.182; p 
 0.573).
idase
Indeed, the majority of peptides with 5-HT secretory
This figure indicates the ranges of peptide-induced exocytotic re-
efficacies of less than 0.5 displayed efficacies for PLDsponses when the secretion of 5-HT (A) and that of -hexosamini-
activation that broadly ranged from 0.19 (M432) to 2.37dase (B) are measured. Data are means  SEM from single experi-
(galparan). Moreover, although M436 and M435 werements performed in triplicate. In these experiments maximal
secretory responses released approximately 80%–90% of the total more potent 5-HT secretagogs than MP, these chimeric
cellular content of either 5-HT or -hexosaminidase. Symbols are constructs were relatively weak activators of PLD.
as follows: (A) squares, MP; right-side-up triangles, M432; upside- In marked contrast to the above comparisons, we
down triangles, M435; diamonds, QLKK-MP; circles, substance P.
observed a clear correlation when we compared effica-(B) squares, MP; triangles, M391; upside-down triangles, M435; dia-
cies for PLD activation and -hexosaminidase secretionmonds, QLKK-MP; circles, substance P.
(Figure 4B). This correlation was statistically confirmed
(Spearman r 
 0.776; p 
 0.004). When we considered
-hexosaminidase, the properties of chimeric con-Is There a Causative Relationship between PLD
Activation and Peptide-Induced Secretion? structs were most illuminating. Thus, the relatively po-
tent -hexosaminidase secretory efficacies of galparan,The activity of PLD has been implicated in the regulated
secretory mechanism linking IgE receptor crosslinking M391, SFLLR-MP, and ZGF-MP correlated with PLD acti-
vation efficacies, which were greater than 1.5. MP S, theto the degranulation of RBL-2H3 [5]. Thus, to provide
further insight to the molecular mechanisms responsible most potent activator of-hexosaminidase secretion, was
also a relatively potent activator of PLD (efficacy index,for the differential activities of peptidyl secretagogs, we
measured phosphatidylbutanol accumulation as an in- 0.58). Significantly, the least potent -hexosaminidase
Differential Peptidyl Secretagogs
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Figure 3. Peptide-Induced Accumulation of Phosphatidylbutanol
This figure indicates the range of efficacies for peptide-induced
phosphatidylbutanol accumulation used as an index of PLD activity.
Data are means  SEM from single experiments performed in tripli-
cate. Symbols are as follows: squares, MP; right-side-up triangles,
galparan; upside-down triangles, MP S; diamonds, ZGF-MP; circles,
substance P.
secretagogs, M436, M432, and QLKK-MP, all displayed
PLD activation efficacies of less than 0.5. These data
indicate that PLD activity does participate in the exocy-
totic mechanism leading to peptide-induced -hexos-
aminidase release from RBL-2H3.
Figure 4. Comparison of Efficacies for Secretion and PLD ActivationDiscussion
This figure reveals the statistically verified correlation between PLD
activation and the secretion of -hexosaminidase but not 5-HT.Numerous basic amphiphilic peptides are reported to
promote secretion from mast cells [1, 31–34]. A common
mechanism that might explain the receptor-independent erties of MP as a peptidyl secretagog and indicate that
the presence of one or more basic residues is not aactions of structurally diverse peptidyl secretagogs is
their interaction with intracellular heterotrimeric G pro- reliable indicator of secretory efficacy in RBL-2H3.
The design of chimeric constructs SFLLR-MP, QLKK-teins. Clearly, such a mechanism would require the effi-
cient membrane translocation of peptides in order to MP, and ZGF-MP utilized sequences known to modulate
secretion [17–19] as amino-terminal extensions of MP.enable access to their intracellular targets. Studies with
a fluorescent analog of substance P have endorsed the SFLLR is an agonist motif of the tethered ligand of the
PAR-1 thrombin receptor [17]. Moreover, the pentapep-above conclusion and have revealed a rapid receptor-
and energy-independent uptake of the peptide into rat tide SFLLR-NH2 induces histamine release from rat peri-
toneal mast cells [35]. QLKK is the amino terminal ofperitoneal mast cells [31]. Subsequent to membrane
translocation, a specific interaction of substance P with QLKKLKEICEKEKKELKKKMDKKRQEKITEAK, a highly
basic peptide derived from the G protein-interacting re-G protein  subunits is believed to induce degranulation
[31]. Significantly, this study identified only two peptide gion of Gq. This sequence, spanning Gln1053–Lys1084 in
the carboxyl terminus of Gq, blocks GTP-dependentsecretagogs, M120 and substance P, which are structur-
ally unrelated to MP and are capable of stimulating se- activation of phospholipase C-1 (PLC-1) by Gq in
vitro [18]. We utilized the sequence QLKK to introducecretion from RBL-2H3. Both M120 and substance P dis-
played relatively low 5-HT secretory efficacies and low an additional pair of basic residues to the MP sequence.
ZGF-NH2 is a dipeptide-competitive metalloendopro-or zero efficacy to promote -hexosaminidase exo-
cytosis. These findings further endorse the unique prop- teinase inhibitor that is reported to modify Ca2-depen-
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dent membrane fusion, release of Ca2from intracellular Moreover, our extensive studies with RBL-2H3 have
failed to detect any endogenously expressed receptorsorganelles, and stimulus-secretion coupling in a variety
of cell types [19, 36]. All of these amino-terminal exten- for peptide hormones or neuropeptides. We therefore
conclude that the differential activities of structural ana-sions had a profound influence on the secretory efficac-
ies of chimeric constructs. As indicated by the proper- logs of MP are a consequence of their selective interac-
tions with multiple intracellular loci of action. In additionties of QLKK-MP, the di-basic sequence QLKK was
clearly deleterious to peptide-induced secretion of both to heterotrimeric G protein  subunits, intracellular tar-
gets for MP analogs with the potential to modulate both5-HT and -hexoasaminidase and PLD activation. A
possible explanation for the pronounced effect of QLKK secretion and PLD activity, include the small GTPases
Rac, Rho, and members of the Rab family [39–41]. More-is a direct influence upon the membrane-associated
secondary structure of the chimera. Indeed, there is over, MP, galparan, and M391 mobilize Ca2 in vitro by
a selective interaction with both Ca2-ATPases and theample evidence that MP adopts a highly amphipathic
helix with all charged residues in a hydrophilic site when ryanodine receptor [14]. Thus, effects upon Ca2homeo-
stasis will probably also contribute to the diverse biolog-it interacts with biological membranes to activate G pro-
teins [reviewed in 15]. However, in this regard it is note- ical activities of MP analogs.
worthy that the sequence SFLLR also provides a single
charged residue adjacent to Ile in SFLLR-MP. Further Significance
experiments to determine whether QLKK-MP has any
direct action upon the activity of PLC-1 are obviously Our findings clearly support the unique properties of
justified. As -hexoasaminidase secretagogs, both MP as a precursor for the synthesis of peptidyl secre-
SFLLR-MP and ZGF-MP were potent and selective, tagogs that selectively activate individual secretory
properties that group these novel constructs together pathways. We introduce the term differential secre-
with MP S, galparan, and M391. SFLLR-MP and ZGF- tagog to describe this unique class of biological agents.
MP were also efficient activators of PLD, a common Basic residues per se are not minimal secretory phar-
property of potent -hexoasaminidase secretagogs. macophores in RBL-2H3. Structural modifications of
Based on our previous studies with galparan and M391 MP, including amino- and carboxy-terminal chimeric
[3, 4], we predict that SFLLR-MP and ZGF-MP will be extensions, have a profound influence upon secretory
potent insulin secretagogs. Moreover, these novel chi- efficacies. A quantitatively dominant group of MP ana-
meric constructs could prove to be valuable probes for logs, including MP S, ZGF-MP, and galparan, selec-
studying the roles of thrombin receptors and metallopro- tively activate the secretion of-hexosaminidase. Chi-
teinases, respectively. meric constructs combining MP with sequences of
Characterization of the secretory efficacies and PLD- human CGRP are relatively potent, non-selective 5-HT
activating potency of MP S, a presumed Gs-selective and -hexosaminidase secretagogs. Comparison of
analog of MP [37], provided intriguing data. MP is a the secretory activities of MP analogs revealed funda-
relatively specific activator of Gi/Go [10] and, since Gi3 mental differences in the molecular regulation of the
has been identified as a specific target for MP in rat exocytosis of 5-HT and -hexosaminidase. Signifi-
peritoneal mast cells [38], we predicted that MP S would cantly, statistical analyses of comparative data con-
possess relatively low secretory efficacy or indeed act firmed that peptide-induced activation of PLD corre-
as a “secretory antagonist.” However, our data clearly lates with the exocytosis of -hexosaminidase but not
indicate that, of all the peptides studied herein, MP S 5-HT. We conclude that structurally modified MP con-
is the most potent and selective -hexoasaminidase structs are unique probes for studying the molecular
secretagog. These data may indicate that the activation regulation of biological phenomena.
of G proteins per se is not a sole determinant of the
secretory efficacies of peptidyl secretagogs. This con-
Experimental Procedures
clusion is supported by our previous study [6], in which
we have shown galparan to be a non-competitive inhibi- Materials
tor of GTPases in rat brain cortical membranes, an effect BK, Des-Arg9BK, [Thi5,8D-Phe7]BK, Lys0BK, AVP, oxytocin, neuroten-
sin, endothelin-1, bombesin, mastoparan, substance P, and sub-that is reversed by MP. Moreover, we have also demon-
stance K were from Bachem (UK) Salmon calcitonin was purchasedstrated [4] that M391 has a complex, concentration-
from Sigma. Cell culture media were obtained from PAA Labora-dependent action upon GTPase activity in Rin m5F cell
tories (Kingston upon Thames, UK). 5-hydroxy[G-3H]tryptamine cre-
membranes. Individual components of this novel effect atinine sulfate ([3H]5-HT, 10.2 Ci/mmol) and [9,10(n)-3H]palmitic acid
of M391 are most likely the selective activation of Gi/ (51.0 Ci/mmol) were from Amersham Pharmacia Biotech UK (Little
Go and suppression of other G proteins, particularly Chalfont, UK).
Gs [4]. Data presented herein provide additional evi-
dence that analogs of MP interact with G proteins at Peptide Synthesis
different loci and that these activities are not reliable Details of the syntheses and biological properties of custom-synthe-
sized peptides are contained in references [2, 4, 7, 20–30]. Materialsindicators of secretory efficacy.
for peptide synthesis were from Novabiochem (UK). MP S [37],Collectively, the chimeric MP analogs used in this
QLKK-MP, SFLLR-MP, and ZGF-MP were manually synthesized (50study include constructs that bind to receptors for AVP,
	M scale) on Rink amide MBHA resin by employing an N--Fmocgalanin, and CGRP. However, in vitro all of these con-
protection strategy with HBTU/HObt activation. Crude peptides
structs are functional antagonists, and peptides such were purified to apparent homogeneity by semipreperative scale
as galparan and M391 are reported to stimulate insulin HPLC [42], and their predicted masses were confirmed by MALDI
TOF mass spectrometry.secretion by a receptor-independent mechanism [3, 4].
Differential Peptidyl Secretagogs
69
Maintenance and Labeling of RBL-2H3 tamate-substituted linear antagonists. Neuropeptides 30,
73–79.The RBL-2H3 cell line was obtained from M.J.O. Wakelam, Univer-
sity of Birmingham. Cells were maintained in DMEM containing 0.1 9. Oppi, C., Wagner, T., Crisari, A., Camerini, B., and Valentini,
G.P.T. (1992). Attenuation of GTPase activity of recombinantmg/ml L-glutamine and supplemented with 10% v/v fetal bovine
serum, 100 U/ml penicillin and 100 	g/ml streptomycin in a humidi- Go-alpha by peptides representing sequence permutations of
mastoparan. Proc. Natl. Acad. Sci. USA 89, 8268–8272.fied atmosphere of 5% CO2 at 37C. For the majority of experiments,
subconfluent cells in 24-well plates were washed with and trans- 10. Higashijima, T., Burnier, J., and Ross, E.M. (1990). Regulation
of Gi and Go by mastoparan, related amphiphilic peptides, andferred into a labeling medium consisting of Hams medium supple-
mented with 0.1% w/v BSA and 10 mM HEPES. Cells were incubated hydrophobic amines—mechanism and structural determinants
of activity. J. Biol. Chem. 265, 14176–14186.for 24 hr in 0.5 ml/well labeling medium containing 0.1 	Ci/ml
[3H]5-HT. 11. Pooga, M., Ha¨llbrink, M., Zorko, M., and Langel, U¨. (1998). Cell
penetration by transportan. FASEB J. 12, 67–77.
12. Lindgren, M., Ha¨llbrink, M., Prochiantz, A., and Langel, U¨. (2000).Secretion Assays
Cell-penetrating peptides. Trends Pharmacol. Sci. 21, 99–103.[3H]5-HT-labeled cells were washed twice, and peptides were added
13. Soomets, U., Lindgren, M., Gallet, X., Ha¨llbrink, M., Elmquist,for a period of 15 min at 37C in a final volume of 0.25 ml. The
A., Balaspiri, L., Zorko, M., Pooga, M., Brasseur, R., and Langel,medium was collected, and cell debris was removed by centrifuga-
U¨. (2000). Deletion analogues of transportan. Biochim. Biophys.tion. Secreted [3H]5-HT was determined in media samples by scintil-
Acta 1467, 165–176.lation spectroscopy.
14. Longland, C.L., Mezna, M., Langel, U¨., Ha¨llbrink, M., Soomets,Secreted -hexosaminidase was assayed in samples of cell me-
U., Wheatley, M., Michelangeli, M., and Howl, J. (1998). Bio-dium. Cellular -hexosaminidase activity was determined in 0.1%
chemical mechanisms of calcium mobilisation induced by mas-v/v Triton X-100 extracts of cell monolayers. For both assays, 5 	l
toparan and chimeric hormone-mastoparan constructs. Cellsamples were transferred into 96-well plates and incubated with 20
Calcium 24, 27–34.	l of 1 mM -nitrophenyl N-acetyl--D-glucosamide in 0.1 M sodium
15. Soomets, U., Ha¨llbrink, M., Zorko, M., and Langel, U¨. (1997).citrate buffer for 1 hr at 37C. Two hundred microliters of a 0.1 M
From galanin and mastoparan to galparan and transportan.Na2CO3/NaHCO3 buffer (pH 10.5) was then added, and -hexosamin-
Curr. Top. Pept. Protein Res. 2, 229–274.idase activity was determined by colorimetric analysis on a microti-
16. Isersky, C., Metzger, H., and Buell, D.N. (1975). Cell cycle-asso-tre plate reader at 405 nm.
ciated changes in receptors for IgE during growth and differenti-
ation of a rat basophilic leukemia cell line. J. Exp. Med. 141,Phospholipase D Assays
1147–1162.The activities of PLD in RBL-2H3 cells labeled with [3H]palmitic acid
17. Scarborough, R.M., Naughton, M.A., Teng, W., Hung, D.T., Rose,were determined with our previously reported transphosphatidyla-
J., Vu, T.K.H., Wheaton, V.I., Turck, C.W., and Coughlin, S.R.tion assay in the presence of 0.3% v/v butan-1-ol [43].
(1992). Tethered ligand agonist peptides—Structural require-
ments for thrombin receptor activation reveal mechanism ofAcknowledgments
proteolytic unmasking of agonist function. J. Biol. Chem. 267,
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18. Wu, D., Jiang, H., Katz, A., and Simon, M.I. (1993). Identification
of critical regions on phospholipase C-1 required for activation
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